Stock Financial Ratios, Dividends, Split History

MRIN / Marin Software Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.70
Volume3,400.00
Market Cap ($M)31.63
Enterprise Value ($M)10.80
Book Value ($M)59.29
Book Value / Share10.31
Price / Book0.55
NCAV ($M)21.75
NCAV / Share3.78
Price / NCAV1.51
Share Statistics
Common Stock Shares Outstanding 5,729,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 5,734,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.50
Return on Assets (ROA)-0.29
Return on Equity (ROE)-0.36
Balance Sheet (mrq) ($M)
Assets77.47
Liabilities18.18
Quick Ration/a
Current Ratio3.15
Income Statement (mra) ($M)
Revenues74,991,000.00
Operating Income-30.27
Net Income-31.49
Earnings Per Share Basic And Diluted-5.59
Cash Flow Statement (mra) ($M)
Cash From Operations-4.87
Cash from Investing-2.52
Cash from Financing-4.87
Identifiers and Descriptors
CUSIP56804T106
Central Index Key (CIK)1389002
Related CUSIPS
56804T906 56804T956

Split History

Stock splits are used by Marin Software Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

AppNexus Deal Highlights the Long-Term Strategy for AT&T Stock

2018-06-27 investorplace
After the past few weeks, investors would be forgiven for ignoring the latest acquisition by AT&T Inc. (NYSE:T). The long-running drama of the company’s acquisition of Time Warner finally has come to an end. Yet AT&T stock tanked on the news, and below $32 the stock is threatening to touch a six-year low. (88-2)

Marin Software: A Race Against Time

2018-05-29 seekingalpha
There are some signs there is a potential for slowing this, but too little to get excited about. (108-1)

Marin Software's (MRIN) CEO Christopher Lien on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Greetings, and welcome to the Marin Software First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. (8-0)

Marin Software:  A Basement Bargain Ripe For Growth Or Acquisition

2018-04-13 seekingalpha
They're in the final stages of beta testing their cross-platform marketing software, which they've spent about $100 million developing the past four years and already sell to big name customers. (8-4)

CUSIP: 56804T106